Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy

被引:0
作者
K S Han
J Y Joung
T S Kim
I G Jeong
H K Seo
J Chung
K H Lee
机构
[1] Urologic Oncology Clinic,
[2] Center for Specific Organs Cancer,undefined
[3] National Cancer Center,undefined
来源
British Journal of Cancer | 2008年 / 98卷
关键词
transitional cell carcinoma; chemotherapy; cisplatin; metastasis;
D O I
暂无
中图分类号
学科分类号
摘要
We investigated the safety and efficacy of a methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) combination regimen as second-line chemotherapy for patients with advanced or metastatic transitional cell carcinoma who failed first-line gemcitabine and cisplatin (GC) chemotherapy. Thirty patients who had progressed or relapsed after GC chemotherapy as first-line treatment were enrolled in this study. The major toxicities were neutropaenia and thrombocytopaenia. A grade 3 or 4 neutropaenia occurred in 19 (63.3%) and a grade 3 or 4 thrombocytopaenia developed in nine patients (30.0%). There were no life-threatening complications during the study. The overall response was 30%. A complete response was achieved in two patients (6.7%) and a partial response in seven (23.3%). The overall disease control rate was 50%. Seven out of 16 patients who had responded previously to GC responded to M-VAC, while 2 out of 14 who had not responded to GC responded to M-VAC. The median response duration was 3.9 months and the median progression-free survival was 5.3 months. The median overall survival was 10.9 months. M-VAC showed encouraging efficacy and reversible toxicities in patients who had progressed after GC chemotherapy and, especially, M-VAC appears to be a reasonable option as a sequential treatment regimen in patients who responded previously to GC chemotherapy.
引用
收藏
页码:86 / 90
页数:4
相关论文
共 50 条
  • [21] Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer
    Ueno, Hideki
    Okusaka, Takuji
    Ikeda, Masafumi
    Morizane, Chigusa
    Ogura, Takashi
    Hagihara, Atsushi
    Tanaka, Tsutomu
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (07) : 515 - 520
  • [22] Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study
    Ngan, RKC
    Yiu, HHY
    Lau, WH
    Yau, S
    Cheung, FY
    Chan, TM
    Kwok, CH
    Chiu, CY
    Au, SK
    Foo, W
    Law, CK
    Tse, KC
    [J]. ANNALS OF ONCOLOGY, 2002, 13 (08) : 1252 - 1258
  • [23] Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP)
    Ki Hong Kim
    Sung Joon Hong
    Kyung Seok Han
    [J]. BMC Cancer, 15
  • [24] CHEMOTHERAPY WITH CISPLATIN, EPIRUBICIN, METHOTREXATE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC TRANSITIONAL CELL-CANCER OF THE BLADDER (TCC)
    LELLI, G
    MELOTTI, B
    PANNUTI, F
    ROSSI, AP
    MAVER, P
    MANNINI, D
    CORRADO, G
    SEVERINI, G
    BERCOVICH, E
    BEGHELLI, R
    CONCETTI, S
    MANFERRARI, F
    NANNI, P
    DESANTIS, P
    MARTINELLI, A
    TANNEBERGER, S
    [J]. JOURNAL OF CHEMOTHERAPY, 1992, 4 (04) : 239 - 243
  • [25] First-line chemotherapy with cisplatin, methotrexate and vinblastine in metastatic bladder cancer
    Pajk, B
    Cufer, T
    Cervek, J
    Zakotnik, B
    [J]. TUMORI, 1996, 82 (05) : 453 - 455
  • [26] The Radiotherapy with Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Treatment Is an Effective Therapeutic Option in Patients with Advanced or Metastatic Bladder Cancer
    Ikeda, Masaomi
    Matsumoto, Kazumasa
    Niibe, Yuzuru
    Satoh, Takefumi
    Fujita, Tetsuo
    Iwamura, Masatsugu
    Ishiyama, Hiromichi
    Kotani, Shoko
    Hayakawa, Kazushige
    Baba, Shiro
    [J]. JOURNAL OF RADIATION RESEARCH, 2011, 52 (05) : 674 - 679
  • [27] Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix
    Choi, C. H.
    Kim, T. -J.
    Leey, S. -J.
    Lee, J. -W.
    Kim, B. -G.
    Lee, J. -H.
    Bae, D. -S.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (03) : 1157 - 1164
  • [28] Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma
    Kakutani, Shigenori
    Fukuhara, Hiroshi
    Taguchi, Satoru
    Nagata, Masayoshi
    Niimi, Aya
    Hattori, Mami
    Miyazaki, Hideyo
    Fujimura, Tetsuya
    Nakagawa, Tohru
    Kume, Haruki
    Igawa, Yasuhiko
    Homma, Yukio
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (03) : 281 - 285
  • [29] Gemcitabine and cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder
    Malik, IA
    Aziz, Z
    Zaidi, SHM
    Sethuraman, G
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (02): : 174 - 177
  • [30] Combination of Gemcitabine and Paclitaxel is a Favorable Option for Patients with Advanced or Metastatic Urothelial Carcinoma Previously Treated with Cisplatin-based Chemotherapy
    Ikeda, Masaomi
    Matsumoto, Kazumasa
    Tabata, Ken-ichi
    Minamida, Satoru
    Fujita, Tetsuo
    Satoh, Takefumi
    Iwamura, Masatsugu
    Baba, Shiro
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (10) : 1214 - 1220